We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Gates Biomanufacturing Facility (GBF) has announced a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic natural killer cells.
US-based biopharmaceutical firm Nkarta Therapeutics has raised $114m in series B funding round to advance its natural killer (NK) cell-based cancer drug candidates into clinical trials.